122 related articles for article (PubMed ID: 19895169)
1. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.
Pour L; Svachova H; Adam Z; Mikulkova Z; Buresova L; Kovarova L; Buchler T; Penka M; Vorlicek J; Hajek R
Neoplasma; 2010; 57(1):29-34. PubMed ID: 19895169
[TBL] [Abstract][Full Text] [Related]
2. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.
Pour L; Svachova H; Adam Z; Almasi M; Buresova L; Buchler T; Kovarova L; Nemec P; Penka M; Vorlicek J; Hajek R
Ann Hematol; 2010 Apr; 89(4):385-9. PubMed ID: 19784651
[TBL] [Abstract][Full Text] [Related]
3. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Ludek P; Hana S; Zdenek A; Martina A; Dana K; Tomas B; Lucie K; Marta K; Jaroslav M; Miroslav P; Jiri V; Roman H
Eur J Haematol; 2010 Apr; 84(4):332-6. PubMed ID: 20015241
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
6. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I; Morabito F; Giuliani N; Terragna C; Omedè P; Palumbo A; Bringhen S; De Paoli L; Martino E; Larocca A; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Dammacco F; Boccadoro M; Vacca A; Ria R
J Hematol Oncol; 2019 Jan; 12(1):4. PubMed ID: 30626425
[TBL] [Abstract][Full Text] [Related]
7. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
9. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Dudek AZ; Mahaseth H
Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
[TBL] [Abstract][Full Text] [Related]
10. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
12. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1347-51. PubMed ID: 12952228
[TBL] [Abstract][Full Text] [Related]
13. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1275-9. PubMed ID: 12952219
[TBL] [Abstract][Full Text] [Related]
14. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor.
Kaga T; Kawano H; Sakaguchi M; Nakazawa T; Taniyama Y; Morishita R
Vascul Pharmacol; 2012 Aug; 57(1):3-9. PubMed ID: 22361334
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Okada M; Matsumori A; Ono K; Miyamoto T; Takahashi M; Sasayama S
Biochem Biophys Res Commun; 1999 Feb; 255(1):80-7. PubMed ID: 10082659
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.
Heeschen C; Dimmeler S; Hamm CW; Boersma E; Zeiher AM; Simoons ML;
Circulation; 2003 Feb; 107(4):524-30. PubMed ID: 12566361
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.
Zhang YW; Su Y; Volpert OV; Vande Woude GF
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12718-23. PubMed ID: 14555767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
